

Original Article  
Microbiology



# Detection and characterization of potential virulence determinants in *Staphylococcus pseudintermedius* and *S. schleiferi* strains isolated from canine otitis externa in Korea

Gi Yong Lee <sup>1</sup>, Soo In Lee <sup>2</sup>, Ji Heon Park <sup>1</sup>, Sun Do Kim <sup>2</sup>, Geun-Bae Kim <sup>2</sup>,  
Soo-Jin Yang <sup>1\*</sup>

<sup>1</sup>Department of Veterinary Microbiology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul 08826, Korea

<sup>2</sup>School of Bioresources and Bioscience, Chung-Ang University, Anseong 17546, Korea



Received: Mar 26, 2023

Revised: Oct 23, 2023

Accepted: Oct 25, 2023

Published online: Nov 10, 2023

\*Corresponding author:

Soo-Jin Yang

Department of Veterinary Microbiology,  
College of Veterinary Medicine and Research  
Institute for Veterinary Science, Seoul National  
University, 1 Gwanak-ro, Gwanak-gu, Seoul  
08826, Korea.

Email: soojinjj@snu.ac.kr

https://orcid.org/0000-0003-3253-8190

## ABSTRACT

**Background:** A recent increase in the occurrence of canine skin and soft tissue infections, including otitis externa and pyoderma, caused by antimicrobial-resistant *Staphylococcus pseudintermedius* and *S. schleiferi* has become a significant public and veterinary health issues.

**Objective:** We investigated the virulence potentials associated with the occurrence of canine otitis externa in *S. pseudintermedius* and *S. schleiferi*.

**Methods:** In this study, the prevalence of genes encoding leukocidins, exfoliative toxins, and staphylococcal enterotoxins (SEs) was investigated using previously characterized *S. pseudintermedius* (n = 26) and *S. schleiferi* (n = 19) isolates derived from canine otitis externa. Susceptibility to cathelicidins (K9CATH and PMAP-36) and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) was also examined in both staphylococcal species.

**Results:** A high prevalence of genes encoding leukocidins (*lukS/F-I*, *lukSI/FI-S*, and *lukS2/F2-S*), exfoliative toxins (*siet*, *expB*, and *sset*), and SEs was identified in both *S. pseudintermedius* and *S. schleiferi* isolates. Notably, *S. pseudintermedius* isolates possessed higher number of SE genes, especially newer SE genes, than *S. schleiferi* isolates harboring *egc* clusters. Although no significant differences in susceptibility to K9CATH and H<sub>2</sub>O<sub>2</sub> were observed between the two isolate groups, *S. pseudintermedius* isolates exhibited enhanced resistance to PMAP-36 compared to *S. schleiferi* isolates.

**Conclusions:** These findings suggest that high a prevalence of various toxin genes together with enhanced resistance to cathelicidins may contribute to the pathogenicity of *S. pseudintermedius* and *S. schleiferi* in canine cutaneous infections.

**Keywords:** *S. pseudintermedius*; *S. schleiferi*; canine otitis externa; virulence

## INTRODUCTION

Staphylococci are frequently implicated in opportunistic skin and soft tissue infections in humans and companion animals [1]. Although *Staphylococcus pseudintermedius*, belonging to the *S. intermedius* group has been recognized as a major cause of cutaneous infections,

**ORCID iDs**

Gi Yong Lee  
<https://orcid.org/0000-0001-5308-0065>  
 Soo In Lee  
<https://orcid.org/0000-0003-4558-5981>  
 Ji Heon Park  
<https://orcid.org/0000-0002-5843-785X>  
 Sun Do Kim  
<https://orcid.org/0000-0003-1394-3844>  
 Geun-Bae Kim  
<https://orcid.org/0000-0001-8531-1104>  
 Soo-Jin Yang  
<https://orcid.org/0000-0003-3253-8190>

**Author Contributions**

Conceptualization: Lee GY, Kim GB, Yang SJ;  
 Formal analysis: Lee GY, Yang SJ; Funding  
 acquisition: Yang SJ; Investigation: Lee GY,  
 Yang SJ; Methodology: Lee GY, Lee SI, Park JH,  
 Kim SD; Project administration: Lee GY, Yang  
 SJ; Supervision: Yang SJ; Writing - original  
 draft: Lee GY, Yang SJ; Writing - review &  
 editing: Kim GB, Yang SJ.

**Conflict of Interest**

The authors declare no conflicts of interest.

**Funding**

This work was supported by a Cooperative  
 Research Program for Agriculture Science &  
 Technology Development (Grant No. PJ012811  
 to S.J.Y) funded by Rural Development  
 Administration, Republic of Korea.

including atopic dermatitis, pyoderma, and otitis externa [2], the recent emergence of *S. schleiferi* in canine otitis externa and pyoderma has become a significant public and veterinary health issues [3,4].

As a major canine-associated cutaneous pathogen, *S. pseudintermedius* possesses various virulence factors, including hemolysins [5], exfoliative toxins (ETs) [6-8], leukocidins [9,10], staphylococcal enterotoxins (SEs) [11], and toxic shock syndrome toxin (TSST) [12]. These virulence factors likely influence severity of skin and soft tissue infections and clinical outcomes. Recently, various *S. pseudintermedius*-specific toxins, such as *S. pseudintermedius* exfoliative toxins (SIET, ExpA, and ExpB) [6-8,13], leukocidins (LukS/F-I) [9,10], and canine SEC (SEC<sub>canine</sub>) [14], have been reported. Although less common than *S. pseudintermedius*, *S. schleiferi* has become a significant canine pathogen carrying multiple potential virulence factors such as TSST and SEs [3,15].

In addition to their array of toxins, the ability of *S. pseudintermedius* and *S. schleiferi* to resist host defense cationic antimicrobial peptides (HD-CAPs) secreted by host keratinocytes and immune cells may play an important role in the pathogenicity and clinical outcomes of canine cutaneous infections [2,3,16]. Previous studies have indicated that staphylococcal isolates with higher levels of resistance to HD-CAPs tend to display increased *in vivo* virulence and carry a higher risk of severe clinical outcomes [2,3,17].

Although several studies on colonization of dogs by *S. pseudintermedius* and *S. schleiferi* have been reported in Korea [2,3,15], to the best of our knowledge, no previous study in Korea has investigated comparative virulence potential of these two major canine pathogens in terms of skin and soft tissue infections. Thus, in the current study, we investigated the carriage rates of major staphylococcal toxin genes, including ETs, leukocidins, SEs, and TSST genes, in *S. pseudintermedius* and *S. schleiferi* strains isolated from canine otitis externa. Moreover, susceptibility to two prototypical cathelicidins of canine (K9CATH) and porcine (PMAP-36) origins was determined in the *S. pseudintermedius* and *S. schleiferi* isolates. Furthermore, hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) resistance profiles were analyzed for the two groups of staphylococcal species.

## MATERIALS AND METHODS

### *S. pseudintermedius* and *S. schleiferi* isolates

A collection of 26 *S. pseudintermedius* and 19 *S. schleiferi* isolates were selected from recently described staphylococcal strains isolated from canine otitis externa in Korea [2,3]. All *S. pseudintermedius* and *S. schleiferi* isolates were identified by using both matrix-assisted laser desorption ionization (MALDI)-Biotyper bacterial identification system (Bruker Daltonics, Germany) and 16S rRNA sequencing (Cosmogenetech, Korea).

All isolates were grown in Mueller-Hinton broth (Difco Laboratories, USA) or tryptic soy broth (Difco Laboratories), depending on the experiment. All broth cultures were grown in Erlenmeyer flasks (< 15% of total flask volume) at 37°C with shaking at 200 rpm.

**Detection of toxin genes in *S. pseudintermedius* and *S. schleiferi* isolates**

Staphylococcal toxin genes in all 45 isolates were detected by polymerase chain reaction (PCR) analyses. Genes encoding ETs (*siet*, *expA*, and *expB*) [6,8,13] and leukocidins (*lukS/F-I*) [18] in *S. pseudintermedius* isolates were detected as previously described. For *S. schleiferi* isolates, specific primer sets were designed to detect the ET (*sset*) and leukocidins (*lukS/F-S*) based on the published genomic data of NCTC12218 (GenBank accession No. LR962863) and TSCC54 (GenBank accession No. AP014944). Specific PCR primer sets and conditions are listed in **Table 1**.

Presence of 18 different SE genes (*sea*, *seb*, *sec*, *sed*, *see*, *seg*, *seh*, *sei*, *selj*, *selk*, *sell*, *selm*, *seln*, *selo*, *selp*, *selq*, *selr*, and *selu*) and the TSST gene (*tst-1*) in the 45 staphylococcal isolates was examined using previously described multiplex PCR assays, with minor modifications [19,20]. Briefly, six separate multiplex PCR assays were employed to detect 18 SE and TSST-1 genes: SE-MIX1 (*sea*, *seb*, *sec*, *sed*, *see*), SE-MIX2 (*selr*, *seln*, *selu*), SE-MIX3 (*selj*, *seg*, *sei*), SE-MIX4 (*selq*, *sell*), SE-MIX5 (*selo*, *selm*, *tst-1*), and SE-MIX6 (*selk*, *selp*, *seh*). PCR amplification of the SE and TSST-1 genes was carried out with initial denaturation at 94°C for 3 min followed by 28 cycles of amplification (denaturation at 95°C for 30 sec, annealing at 53°C for 45 sec, and extension at 72°C for 45 sec) and a final extension at 72°C for 10 min. Reference genomic DNA samples from previously characterized *S. aureus* strains (MW2: *sea*, *seh*, *selk*, *selp*; COL: *seb*; N315: *sec*, *selm*, *selo*; FRI472: *sed*, *seg*, *sei*, *selj*, *seln*, *selr*, *selu*; FRI913: *see*, *sell*, *selq*, *tst-1*) were used as positive controls in each multiplex PCR reaction. Representative results of the PCR-detection are shown in **Supplementary Fig. 1**.

**Table 1.** Primer sets and conditions of polymerase chain reaction amplification for staphylococcal toxins for *S. pseudintermedius* and *S. schleiferi*

Name	Gene	Primer	Sequence (5'-3')	Size (bp)	References
<i>S. pseudintermedius</i>	<i>lukS-I</i>	SP_lukS-F	TGTAAGCAGCAGAAAATGGGG	503	[9]
		SP_lukS-R	GCCCGATAGGACTTCTTACAA		
	<i>lukF-I</i>	SP_lukF-F	CCTGTCTATGCCGCTAATCAA	572	[9]
		SP_lukF-R	AGGTCATGGAAGCTATCTCGA		
	<i>siet</i>	SP_siet-F	ATGGAATAATTTAGCGGCATCTGG	359	[41]
		SP_siet-R	CCATTACTTTTCGCTTGTGTGC		
	<i>expA</i>	SP_expA-F	CAATCATATAATGAGGAAGAAATATTAAGAAAGCAA	737	[7]
		SP_expA-R	TTCTTCTGTAAATTTAGCTCTTTTTTCAAGTCTTC		
	<i>expB</i>	SP_expB-F	CGCCTGGCGTATATGCTAAA	595	This study
		SP_expB-R	AAGCCAGATCCTGAATTTCC		
95°C for 30 sec, (95°C for 30 sec, 52°C for 45 sec, 72°C for 45 sec) X 32 cycles, and 72°C for 10 min					
<i>S. schleiferi</i>	<i>lukS1-S</i>	SS_lukS1-S-F	TATTGTCGCCGAACAACAAA	510	This study
		SS_lukS1-S-R	TTAACGCCCATGCTACATT		
	<i>lukF1-S</i>	SS_lukF1-S-F	TGCAGATGCAGATCGATTTAATA	796	This study
		SS_lukF1-S-R	AGCAGTGTGTTTTGCCAAT		
	<i>lukS2-S</i>	SS_lukS2-S-F	GCTATATAAAGCCCGAACA	486	This study
		SS_lukS2-S-R	CTGTTGTAAGGAAAGACGGA		
	<i>lukF2-S</i>	SS_lukF2-S-F	ACTTTCAAGTCACGCTTTTG	651	This study
		SS_lukF2-S-R	ATAAAGTTCACCGGCATT		
	<i>sset</i>	SS_sset-F	ATGGAATAATTTAGCGGCATCTGG	243	This study
		SS_sset-R	CCATTACTTTTCGCTTGTGTGC		
95°C for 30 sec, (95°C for 30 sec, 53°C for 45 sec, 72°C for 45 sec) X 32 cycles, and 72°C for 10 min					
<i>S. pseudintermedius</i> and <i>S. schleiferi</i>	<i>eta</i>	eta-F	CTAGTGCATTGTATTCAAGACG	119	[42]
		eta-R	TGCATTGACACCATAGTACTTATTC		
	<i>etb</i>	etb-F	ACGGCTATATACATTCAATCAATG	262	[42]
		etb-R	AAAGTTATTCATTTAATGCATGTCTC		
	<i>tst-1</i>	tst-F	AAGCCCTTTGTTGCTTGCG	447	[42]
		tst-R	ATCGAACTTTGGCCCATACTTT		
95°C for 30 sec, (95°C for 30 sec, 55°C for 30 sec, 72°C for 30 sec) X 30 cycles, and 72°C for 10 min					

### **In vitro susceptibilities to K9CATH and PMAP-36**

Cathelicidins play pivotal roles in host innate immune defense against bacterial pathogens during skin and soft tissue infections [21]. Two prototypical cathelicidins, K9CATH (RLKELITTGGQKIGEKIRRIGQRIKDFFKNLQPREEKS) [22] and PMAP-36 (GRFRRLRKKTRKRLKKIGKVLKWIPPVIGSIPLGCG) [23], were synthesized at GL Biochem (China) with a purity of > 95%.

To assess potential differences in susceptibility to cathelicidins between the two groups of staphylococci, *in vitro* survival assays were performed for all 26 *S. pseudintermedius* and 19 *S. schleiferi* isolates against K9CATH and PMAP-36 at pH 5.5. *In vitro* susceptibility to K9CATH and PMAP-36 was determined using a 2 h survival assay in RPMI-1640 medium (Sigma-Aldrich, USA) containing 5% Luria-Bertani broth as previously described [24]. To mimic the physiological conditions of canine otitis externa and acidic phagolysosomes [25], assay conditions were adjusted to pH 5.5 using 2-(*N*-morpholino) ethanesulfonic acid (MES) buffer. Briefly, the assays were performed with 0.25 µg/mL of K9CATH or PMAP-36 using an initial staphylococcal inoculum of  $\sim 5 \times 10^3$  CFUs. Cathelicidin concentrations were determined based on extensive preliminary experiments. Data represent the relative percentage of surviving staphylococcal cells from cathelicidin-treated versus untreated conditions ( $\pm$  SD). A minimum of three independent experiments were performed for each isolate.

### **In vitro susceptibility to hydrogen peroxide**

*In vitro* susceptibility to hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) was determined for all *S. pseudintermedius* and *S. schleiferi* isolates, as previously described [26]. Briefly,  $\sim 5 \times 10^7$  CFUs of overnight-grown *S. pseudintermedius* or *S. schleiferi* cells were incubated with 1.5% H<sub>2</sub>O<sub>2</sub> at 37°C. After 2 h of incubation, 1,000 U/mL of catalase (Sigma-Aldrich) was added to remove all residual H<sub>2</sub>O<sub>2</sub> in the solution. To enumerate surviving staphylococcal cells, reaction solutions were diluted ten-fold, then spread on tryptic soy agar plates. Data were presented as mean percentages of surviving cells of H<sub>2</sub>O<sub>2</sub>-treated versus untreated cells ( $\pm$  SD). Three independent experiments were performed for all staphylococcal isolates.

### **Statistical analysis**

Two-sided Mann-Whitney *U* tests of variance with Duncan's *post hoc* correction were performed for multiple comparisons using IBM SPSS Statistics 25 software (USA). The significance threshold was set at  $p < 0.05$ .

## **RESULTS**

### **Toxin gene profiles of staphylococcal isolates**

As shown in **Table 2**, 43/45 (95.6%) staphylococcal isolates from canine otitis externa possessed leukocidin genes. Only one *S. pseudintermedius* and one *S. schleiferi* isolates tested were negative for all leukocidin genes. All 18 *S. schleiferi* isolates carrying *lukS1-S* and *lukF1-S* genes were also positive for *lukS2-S* and *lukF2-S*. Similar to the high prevalence of leukocidin genes, all 26 *S. pseudintermedius* isolates and 18/19 *S. schleiferi* isolates were positive for the ET genes *siet* and *sset*, respectively (**Table 2**). Interestingly, although 12 *S. pseudintermedius* isolates (46.2%) were positive for *expB*, none of the *S. pseudintermedius* isolates carried *expA*.

In addition to the leukocidin and ET genes, a high prevalence of SE genes was observed in *S. pseudintermedius* and *S. schleiferi* isolates (**Table 2**). At least one of the 18 SE genes was detected in

**Table 2.** Comparative profiles of SE, TSST, leukocidin, and exfoliative toxin genes between *S. pseudintermedius* and *S. schleiferi* isolates obtained from canine otitis externa

Toxin	No. of SE-positive strain (%)		
	<i>S. pseudintermedius</i> (n = 26)	<i>S. schleiferi</i> (n = 19)	Total (n = 45)
<b>SEs</b>			
<i>sea</i>	-	-	-
<i>seb</i>	-	-	-
<i>sec</i>	1 (4)	-	1 (2.2)
<i>sed</i>	-	-	-
<i>see</i>	15 (57.7)	-	15 (33.3)
<i>seg</i>	25 (96.2)	10 (52.6)	35 (77.8)
<i>seh</i>	6 (23.1)	-	6 (13.3)
<i>sei</i>	25 (96.2)	10 (52.6)	35 (77.8)
<i>selj</i>	-	-	-
<i>selk</i>	-	2 (11)	2 (4.4)
<i>sell</i>	1 (3.8)	6 (31.6)	7 (15.6)
<i>selm</i>	25 (96.2)	14 (73.7)	39 (86.7)
<i>seln</i>	24 (92.3)	-	24 (53.3)
<i>selo</i>	-	1 (5)	1 (2.2)
<i>selp</i>	8 (30.8)	-	8 (17.8)
<i>selq</i>	1 (3.8)	6 (31.6)	7 (15.6)
<i>selr</i>	-	-	-
<i>selu</i>	22 (84.6)	-	22 (48.9)
<b>TSST</b>			
<i>tst-1</i>	-	-	-
<b>Leukocidins</b>			
<i>lukS-I</i>	25 (96.2)	ND	25 (55.6)
<i>lukF-I</i>	25 (96.2)	ND	25 (55.6)
<i>lukS1-S</i>	ND	18 (94.7)	18 (40)
<i>lukS2-S</i>	ND	18 (94.7)	18 (40)
<i>lukF1-S</i>	ND	18 (94.7)	18 (40)
<i>lukF2-S</i>	ND	18 (94.7)	18 (40)
<b>Exfoliative toxins</b>			
<i>siet</i>	26 (100)	ND	26 (57.8)
<i>expA</i>	-	ND	-
<i>expB</i>	12 (46.2)	ND	12
<i>sset</i>	ND	18 (94.7)	18 (40)
<i>eta</i>	-	-	-
<i>etb</i>	-	-	-

SE, staphylococcal enterotoxin; TSST, toxic shock syndrome toxin; ND, not detected.

25/26 *S. pseudintermedius* (96.2%) isolates and 16/19 *S. schleiferi* (84.2%) isolates (**Tables 3 and 4**). Among the 18 screened SE and TSST genes, *selm* was most frequently detected in both *S. pseudintermedius* (25/26, 96.2%) and *S. schleiferi* (14/19, 73.7%) isolates, followed by *seg* and *sei* (96.2% in *S. pseudintermedius* and 52.6% in *S. schleiferi* for each gene). While carriage of three SE genes (*seg-sei-selm*) was identified in 96.2% (25/26) and 47.4% (9/19) of *S. pseudintermedius* and *S. schleiferi* isolates, respectively, carriage of 5 (*seg-sei-selm-seln-selu*) and 7 (*sec-seg-sei-sell-selm-seln-selu*) SE genes was detected only in *S. pseudintermedius* isolates (84.6% and 4% of the isolates, respectively) (**Tables 3 and 4**). Although high carriage rates of *see* (15/26, 57.7%), *seln* (24/26, 92.3%), and *selu* (22/26, 84.6%) were identified in *S. pseudintermedius* isolates, none of the *S. schleiferi* isolates possessed these three SE genes. One *S. pseudintermedius* (SP21) and three *S. schleiferi* (SS7, SS13, and SS14) isolates were negative for all SE genes (**Tables 3 and 4**). All *S. pseudintermedius* and *S. schleiferi* isolates were negative for TSST gene. No significant correlations were found between the prevalence of toxin genes (leukocidins, ETs, and SEs) and profiles of sequence types (MLST) among the *S. pseudintermedius* isolates (**Table 3**). Similarly, methicillin resistance due to harboring SCCmec V did not affect toxin gene profiles in either *S. pseudintermedius* (**Table 3**) or *S. schleiferi* (**Table 4**).

**Table 3.** Profiles of genes encoding staphylococcal toxins in *S. pseudintermedius* strains isolated from canine otitis externa

Strain	MLST <sup>a</sup>	SCCmec <sup>a</sup>	Toxins		
			SEs	Leukocidin	Exfoliative toxin
SP1	ST568	V	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP2	ST551	V	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP3	ST568	V	see, seg, seh, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP4	ST568	V	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP5	ST429	-	seg, sei, selm, seln, selp, selu	lukS-1, lukF-1	siet
SP6	ST155	-	sec, seg, sei, sell, selm, seln, selu	lukS-1, lukF-1	siet
SP7	ST155	-	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP8	ST580	V	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet, expB
SP9	ST774	-	see, seg, sei, selm, seln, selu	lukF-1	siet
SP10	ST706	V	seg, sei, selm, seln, selq, selu	lukS-1, lukF-1	siet, expB
SP11	ST316	V	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP12	ST133	-	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet, expB
SP13	ST17	NT	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet, expB
SP14	ST72	V	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP15	ST76	-	seg, sei, selm, seln, selu	lukS-1, lukF-1	siet, expB
SP16	ST1	V	see, seg, sei, selm, seln, selu	lukS-1, lukF-1	siet, expB
SP17	ST566	V	-	lukS-1, lukF-1	siet
SP18	ST571	V	seg, sei, selm, seln, selp, selu	lukS-1, lukF-1	siet, expB
SP19	ST76	V	see, seg, sei, selm, selp	lukS-1, lukF-1	siet
SP20	NT	V	see, seg, sei, selm, seln, selp, selu	lukS-1, lukF-1	siet, expB
SP21	NT	-	seg, sei, selm, seln, selu	-	siet
SP22	NT	-	seg, seh, sei, selm, seln, selp, selu	lukS-1, lukF-1	siet, expB
SP23	NT	-	seg, seh, sei, selm, seln, selu	lukS-1, lukF-1	siet
SP24	ST195	-	seg, seh, sei, selm, seln, selp, selu	lukS-1, lukF-1	siet, expB
SP25	ST809	V	seg, seh, sei, selm, seln, selp	lukS-1, lukF-1	siet, expB
SP26	ST903	NT	see, seg, seh, sei, selm, seln, selp	lukS-1, lukF-1	siet, expB

SE, staphylococcal enterotoxin; TSST, toxic shock syndrome toxin; NT, nontypeable.

<sup>a</sup>Profiles of sequence types and SCCmec types were previously published [4].

**Table 4.** Profiles of genes encoding staphylococcal toxins in *S. schleiferi* strains isolated from canine otitis externa

Strain	SCCmec <sup>a</sup>	Toxins		
		SEs <sup>a</sup>	Leukocidin	Exfoliative toxin
SS1	-	seg, sei, selk, sell, selm, selq	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS2	V	seg, sei, sell, selm, selq	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS3	V	seg, sei, sell, selm, selq	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS4	V	seg, sei, sell, selm, selq	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS5	-	seg, sei, sell, selm, selq	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS6	VII	seg, sei, sell, selq	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS7	-	-	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS8	-	seg, sei, selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS9	-	seg, sei, selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS10	V	seg, sei, selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS11	-	selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS12	-	selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS13	-	-	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS14	-	-	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS15	-	seg, sei, selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS16	-	selo	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS17	-	selk, selm	-	-
SS18	-	selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset
SS19	-	selm	lukS1-S, lukF1-S, lukS2-S, lukF2-S	sset


SE, staphylococcal enterotoxin; TSST, toxic shock syndrome toxin.

<sup>a</sup>Profiles of SCCmec and SE types were previously published [6].

### Susceptibilities to cathelicidins

As shown in **Fig. 1A**, no significant difference in susceptibility to K9CATH (0.25 µg/mL) was observed between *S. pseudintermedius* and *S. schleiferi* isolates ( $p = 0.474$ ). In contrast, *S.*





**Fig. 1.** *In vitro* susceptibility of *S. pseudintermedius* and *S. schleiferi* isolates to K9CATH (A) and PMAP-36 (B). The *in vitro* susceptibility assays were performed with 0.25 µg/mL of K9CATH or PMAP-36 using an initial bacterial inoculum of  $\sim 5 \times 10^3$  CFUs at pH 5.5. Each bar represents the mean  $\pm$  SD of three independent experiments on each isolate.

\* $p < 0.05$ .


*pseudintermedius* isolates displayed significantly higher resistance when treated with PMAP-36 (0.25 µg/mL) at pH 5.5 ( $p = 0.012$ ) (**Fig. 1B**).

### Susceptibility to hydrogen peroxide

As shown in **Fig. 2**, 26 *S. pseudintermedius* and 19 *S. schleiferi* isolates exhibited varying survival rates after a 2 h exposure to 1.5% H<sub>2</sub>O<sub>2</sub>. No significant difference in mean resistance to H<sub>2</sub>O<sub>2</sub> was observed between *S. pseudintermedius* and *S. schleiferi* isolates.

## DISCUSSION

Coagulase-positive *S. pseudintermedius* has frequently been implicated in various skin and soft tissue infections in dogs [5]. Although at a lower frequency than *S. pseudintermedius*, coagulase-negative *S. schleiferi* also causes a significant number of dermatological infections in dogs [4,27]. While the prevalence of *S. pseudintermedius* and *S. schleiferi* in infected dogs and their antimicrobial resistance have been actively investigated [4,5,27], few studies have focused on the virulence factors involved in the pathogenesis of these two canine-associated staphylococcal species.



**Fig. 2.** *In vitro* susceptibility of *S. pseudintermedius* and *S. schleiferi* isolates to hydrogen peroxide ( $H_2O_2$ ). Staphylococcal cells ( $\sim 5 \times 10^7$  CFUs) were incubated with 1.5%  $H_2O_2$  at 37°C for 2 h and surviving cells were counted on TSA plates. Data represent the mean  $\pm$  SD of three independent experiments. NS, not significant.

In this study, we examined 26 *S. pseudintermedius* [2] and 19 *S. schleiferi* [3] isolates collected from canine otitis externa cases in Korea to assess the virulence potential associated with canine skin and soft tissue infections.

Among the wide array of virulence determinants, pore-forming toxins, such as ETs and superantigens (SAGs), have been known to be involved in skin and soft tissue infections [28]. Similar to the Panton-Valentine leukocidin in *S. aureus*, a bi-component leukocidin from *S. intermedius*, LukS/F-I, has been well characterized [10,18]. Consistent with previous studies, which reported a high prevalence (92.3%–100%) of LukS/F-I in *S. pseudintermedius* isolates recovered from healthy dogs [5,29,30] and dogs with clinical symptoms [5,9,31], all *S. pseudintermedius* isolates in this study were positive for LukS/F-I genes, except for one *S. pseudintermedius* isolate (SP21) (Tables 2 and 3). Interestingly, two different types of leukocidins, LukS/F1-S and LukS/F2-S, which share amino acid sequence similarities of 54%–59% and 56%–58% with LukS/F-I of *S. pseudintermedius*, respectively, were detected in *S. schleiferi* isolates (Tables 2 and 4). The specific role of LukS/F1-S and LukS/F2-S in the context of canine skin and soft tissue infections need to be further characterized in the future study.

In addition to leukocidins, ETs in *S. pseudintermedius* such as SIET, ExpA, and ExpB have been proposed to be involved in the clinical outcomes of cutaneous infections. Similar to previous studies, which reported 92.3%–100% SIET [5,29–32], all 26 *S. pseudintermedius* and 18/19 *S. schleiferi* isolates in this study possessed *siet* or *sset* (Table 2). However, it has been demonstrated that SIET exhibits very limited enzymatic activity toward canine Dsg 1, which is expressed throughout the epidermal layer in canine skin [7]. The cytotoxic and exfoliative effects of *sset* have not yet been elucidated. Although the prevalence of ExpA and ExpB in *S. pseudintermedius* isolates was lower than that of SIET in previous studies [6,8,29–32], recent studies have revealed that both ExpA and ExpB are capable of digesting canine Dsg1 [6–8]. In this study, while none of the *S. pseudintermedius* isolates carried *expA*, 46.2% (12/26 isolates) of *S. pseudintermedius* isolates were positive for *expB* (Table 2), which was significantly higher than those of previous studies (7.6%–23.2%) [6,31]. These results indicate a high prevalence of genes encoding leukocidins and ETs in *S. pseudintermedius* and *S. schleiferi* isolates regardless of their genetic background and methicillin resistance.



As shown in **Tables 3** and **4**, *S. pseudintermedius* isolates tend to have more SE genes than *S. schleiferi* isolates. However, the overall prevalences of *S. pseudintermedius* and *S. schleiferi* isolates carrying at least one SE gene were 96.2% (25/26) and 94.7% (18/19), respectively. Previous studies have reported a 48.8% - 65.7% SE gene prevalence with the highest frequency of *selq* in *S. pseudintermedius* isolates [11, 33]. In our study, the most frequently detected SE genes were *selm*, *seg*, and *sei* in both *S. pseudintermedius* and *S. schleiferi* isolates. Notably, a distinctive type of SEC among canine-associated staphylococci (SEC<sub>canine</sub>) [14] was identified in one *S. pseudintermedius* isolate (SP6) (**Table 3**). DNA sequencing analysis of SEC<sub>canine</sub> in the SP6 strain confirmed 100% match to the previously reported amino acid sequence of SEC<sub>canine</sub>-positive *S. pseudintermedius* strain (NCBI Reference Sequence WP\_130882709). The superantigenic activity of SEC<sub>canine</sub> has been suggested to be involved in the clinical severity of canine skin infections [14]. The presence of multiple SE genes in the enterotoxin gene cluster (*egc* locus) was also identified in both staphylococcal species [34]. The *egc* has been described to contain the so-called new enterotoxin genes, such as *seg*, *sei*, *sem*, *sen*, *seo*, and *seu*, in *S. aureus* [34]. The *egc* is usually located on the genomic island and is incorporated into the chromosome as a prophage. Previous studies also revealed most frequent detection of the SE genes included within the *egc*, such as *seg*, *sei*, *selm*, *sen*, and *seo*, in livestock-associated *S. aureus* [35]. In this study, the *egc* clusters comprised of *seg-sei-selm* were detected in 96.1% (25/26) and 47.4% (9/19) of *S. pseudintermedius* and *S. schleiferi* isolates, respectively, suggesting horizontal transmission of *egc* clusters among different species of staphylococci. The *seg-sei-selm-selm-selu* cluster was detected only in *S. pseudintermedius* isolates (21/26, 80.8%), suggesting that *S. pseudintermedius* may have enhanced frequency of horizontal SE gene transfer compared to *S. schleiferi*.

It should be recognized that the presence of genes encoding leukocidins, ETs, and SEs in *S. pseudintermedius* and *S. schleiferi* isolates may not directly correlate with the toxin production. In addition, there is a possibility that sequence variations in SE genes may not have been detected with the PCR-based method [36]. Future studies are warranted to investigate SE gene sequence variations using whole genome sequence analyses [37] and various factors affecting expression of these toxin genes in the context of canine skin and soft tissue infections.

The ability to survive bactericidal activity of cathelicidins is important for the onset and persistence of staphylococcal skin infections [21]. It has been shown that an endogenous canine cathelicidin, K9CATH, exerts antimicrobial properties against pathogens implicated in canine skin and ear infections [2,3,16,22,38]. Although previous studies have evaluated the antimicrobial properties of K9CATH at pH 7.4 [2,3,16,22,38], bactericidal activity of K9CATH has not been examined under acidic conditions, which represent the pH range of the external ear canals in dogs with otitis externa [25,39]. Although varying degrees of viability were identified among the staphylococcal isolates at pH 5.5, there was no significant difference in K9CATH susceptibility between *S. pseudintermedius* and *S. schleiferi* isolate groups (**Fig. 1A**). However, *S. pseudintermedius* isolates displayed significantly higher resistance than *S. schleiferi* isolates when exposed to PMAP-36 (0.25 µg/mL) at pH5.5 (**Fig. 1B**). The different susceptibility profiles of K9CATH and PAMP-36 indicate that cathelicidins originating from different animal species may exert bactericidal activity against *S. pseudintermedius* and *S. schleiferi* via distinct mechanisms.

Given the impact of innate immune responses, such as oxidative bursts in the phagolysosomes of phagocytes, on the pathogenesis of staphylococci during skin and soft tissue infections [40], *in vitro* susceptibility to H<sub>2</sub>O<sub>2</sub> was examined in *S. pseudintermedius* and *S. schleiferi* isolates. As shown in **Fig. 2**, no significant difference in susceptibility to H<sub>2</sub>O<sub>2</sub> was observed between

the two species of staphylococci. The similar levels of resistance to H<sub>2</sub>O<sub>2</sub> between the *S. pseudintermedius* and *S. schleiferi* isolates may be an example of convergent adaptation, as both isolate groups were obtained from clinical canine otitis externa, which promoted the adaptation of the isolates to various innate host immune defense of canine ear canals.

In conclusion, the results of this study provide important insights into the virulence potentials of *S. pseudintermedius* and *S. schleiferi* isolates collected from canine cutaneous infections. Our results suggest that: i) genes encoding leukocidins and ETs are highly prevalent in both *S. pseudintermedius* and *S. schleiferi* isolates obtained from canine otitis externa; ii) *S. pseudintermedius* isolates tended to have higher numbers of SE genes, especially non-classical SE genes, than *S. schleiferi* isolates by harboring *egc* clusters; iii) there are no differences in susceptibilities to K9CATH and H<sub>2</sub>O<sub>2</sub> between *S. pseudintermedius* and *S. schleiferi* isolates, indicating both species have developed strategies to overcome the canine innate immune response; iv) enhanced resistance to PMAP-36 in *S. pseudintermedius* versus *S. schleiferi* indicates that *S. pseudintermedius* might have advantage to adapt to different host species.

## SUPPLEMENTARY MATERIAL

### Supplementary Fig. 1

Polymerase chain reaction -detection of SE, leukocidin, and exfoliative toxin genes. (A) Lanes 1-6, SE genes from reference *S. aureus* strains; lane 8, *sec* of SP6 strain; Lanes 9-12, *seg*, *sei*, *sel*, and *sem* genes of SS8 strain; and Lane 13-14, *seln* and *selu* genes of SP3 strain. (B) lanes 1-6, toxin genes of SP8 strains and lanes 7-11, toxin genes of SS4 strain. Specific primers set were designed based on public whole genome sequence data of *S. pseudintermedius* (strain HKU10-03; GenBank accession No. CP002439 [*lukS-I* and *lukF-I*], strain ED99; GenBank accession No. CP002478 [*siet*], strain AI14; GenBank accession No. CP031604 [*expA*], and strain MS5134; GenBank accession No. AB569087 [*expB*]) and *S. schleiferi* (NCTC12218; GenBank accession No. LR962863 [*sset*], and TSCC54; GenBank accession No. AP014944 [*lukS1-S*, *lukF1-S*, *lukS2-S*, and *lukF2-S*]).

[Click here to view](#)

## REFERENCES

1. Parlet CP, Brown MM, Horswill AR. Commensal staphylococci influence *Staphylococcus aureus* skin colonization and disease. *Trends Microbiol.* 2019;27(6):497-507.  
[PUBMED](#) | [CROSSREF](#)
2. Lee GY, Yang SJ. Comparative assessment of genotypic and phenotypic correlates of *Staphylococcus pseudintermedius* strains isolated from dogs with otitis externa and healthy dogs. *Comp Immunol Microbiol Infect Dis.* 2020;70:101376.  
[PUBMED](#) | [CROSSREF](#)
3. Lee GY, Lee HH, Hwang SY, Hong J, Lyoo KS, Yang SJ. Carriage of *Staphylococcus schleiferi* from canine otitis externa: antimicrobial resistance profiles and virulence factors associated with skin infection. *J Vet Sci.* 2019;20(2):e6.  
[PUBMED](#) | [CROSSREF](#)
4. Penna B, Mendes W, Rabello R, Lilenbaum W. Carriage of methicillin susceptible and resistant *Staphylococcus schleiferi* among dog with or without topic infections. *Vet Microbiol.* 2013;162(1):298-299.  
[PUBMED](#) | [CROSSREF](#)
5. Wang Z, Guo L, Li J, Li J, Cui L, Dong J, et al. Antibiotic resistance, biofilm formation, and virulence factors of isolates of *staphylococcus pseudintermedius* from healthy dogs and dogs with keratitis. *Front Vet Sci.* 2022;9:903633.  
[PUBMED](#) | [CROSSREF](#)

6. Iyori K, Hisatsune J, Kawakami T, Shibata S, Murayama N, Ide K, et al. Identification of a novel *Staphylococcus pseudintermedius* exfoliative toxin gene and its prevalence in isolates from canines with pyoderma and healthy dogs. *FEMS Microbiol Lett.* 2010;312(2):169-175.  
[PUBMED](#) | [CROSSREF](#)
7. Iyori K, Futagawa-Saito K, Hisatsune J, Yamamoto M, Sekiguchi M, Ide K, et al. *Staphylococcus pseudintermedius* exfoliative toxin EX1 selectively digests canine desmoglein 1 and causes subcorneal clefts in canine epidermis. *Vet Dermatol.* 2011;22(4):319-326.  
[PUBMED](#) | [CROSSREF](#)
8. Futagawa-Saito K, Makino S, Sunaga F, Kato Y, Sakurai-Komada N, Ba-Thein W, et al. Identification of first exfoliative toxin in *Staphylococcus pseudintermedius*. *FEMS Microbiol Lett.* 2009;301(2):176-180.  
[PUBMED](#) | [CROSSREF](#)
9. Futagawa-Saito K, Sugiyama T, Karube S, Sakurai N, Ba-Thein W, Fukuyasu T. Prevalence and characterization of leukotoxin-producing *Staphylococcus intermedius* in Isolates from dogs and pigeons. *J Clin Microbiol.* 2004;42(11):5324-5326.  
[PUBMED](#) | [CROSSREF](#)
10. Abouelkhair MA, Bemis DA, Giannone RJ, Frank LA, Kania SA. Characterization of a leukocidin identified in *Staphylococcus pseudintermedius*. *PLoS One.* 2018;13(9):e0204450.  
[PUBMED](#) | [CROSSREF](#)
11. Tanabe T, Toyoguchi M, Hirano F, Chiba M, Onuma K, Sato H. Prevalence of staphylococcal enterotoxins in *Staphylococcus pseudintermedius* isolates from dogs with pyoderma and healthy dogs. *Microbiol Immunol.* 2013;57(9):651-654.  
[PUBMED](#) | [CROSSREF](#)
12. Yoon JW, Lee GJ, Lee SY, Park C, Yoo JH, Park HM. Prevalence of genes for enterotoxins, toxic shock syndrome toxin 1 and exfoliative toxin among clinical isolates of *Staphylococcus pseudintermedius* from canine origin. *Vet Dermatol.* 2010;21(5):484-489.  
[PUBMED](#) | [CROSSREF](#)
13. Terauchi R, Sato H, Hasegawa T, Yamaguchi T, Aizawa C, Maehara N. Isolation of exfoliative toxin from *Staphylococcus intermedius* and its local toxicity in dogs. *Vet Microbiol.* 2003;94(1):19-29.  
[PUBMED](#) | [CROSSREF](#)
14. Edwards VM, Deringer JR, Callantine SD, Deobald CF, Berger PH, Kapur V, et al. Characterization of the canine type C enterotoxin produced by *Staphylococcus intermedius* pyoderma isolates. *Infect Immun.* 1997;65(6):2346-2352.  
[PUBMED](#) | [CROSSREF](#)
15. Han JI, Yang CH, Park HM. Prevalence and risk factors of *Staphylococcus* spp. carriage among dogs and their owners: a cross-sectional study. *Vet J.* 2016;212:15-21.  
[PUBMED](#) | [CROSSREF](#)
16. Santoro D, Maddox CW. Canine antimicrobial peptides are effective against resistant bacteria and yeasts. *Vet Dermatol.* 2014;25(1):35-e12.  
[PUBMED](#) | [CROSSREF](#)
17. Kang KM, Park JH, Kim SH, Yang SJ. Potential role of host defense antimicrobial peptide resistance in increased virulence of health care-associated MRSA strains of sequence type (ST) 5 versus livestock-associated and community-associated MRSA strains of ST72. *Comp Immunol Microbiol Infect Dis.* 2019;62:13-18.  
[PUBMED](#) | [CROSSREF](#)
18. Prevost G, Bouakham T, Piemont Y, Monteil H. Characterisation of a synergohymenotropic toxin produced by *Staphylococcus intermedius*. *FEBS Lett.* 1995;376(3):135-140.  
[PUBMED](#) | [CROSSREF](#)
19. Park JY, Fox LK, Seo KS, McGuire MA, Park YH, Rurangirwa FR, et al. Detection of classical and newly described staphylococcal superantigen genes in coagulase-negative staphylococci isolated from bovine intramammary infections. *Vet Microbiol.* 2011;147(1-2):149-154.  
[PUBMED](#) | [CROSSREF](#)
20. Lee SI, Kim SD, Park JH, Yang SJ. Species distribution, antimicrobial resistance, and enterotoxigenicity of non-*aureus* staphylococci in retail chicken meat. *Antibiotics (Basel).* 2020;9(11):809.  
[PUBMED](#) | [CROSSREF](#)
21. Otto M. *Staphylococcus* colonization of the skin and antimicrobial peptides. *Expert Rev Dermatol.* 2010;5(2):183-195.  
[PUBMED](#) | [CROSSREF](#)
22. Sang Y, Teresa Ortega M, Rune K, Xiau W, Zhang G, Soulages JL, et al. Canine cathelicidin (K9CATH): gene cloning, expression, and biochemical activity of a novel pro-myeloid antimicrobial peptide. *Dev Comp Immunol.* 2007;31(12):1278-1296.  
[PUBMED](#) | [CROSSREF](#)

23. Lv Y, Wang J, Gao H, Wang Z, Dong N, Ma Q, et al. Antimicrobial properties and membrane-active mechanism of a potential  $\alpha$ -helical antimicrobial derived from cathelicidin PMAP-36. *PLoS One*. 2014;9(1):e86364.  
[PUBMED](#) | [CROSSREF](#)
24. Lin L, Nonejuie P, Munguia J, Hollands A, Olson J, Dam Q, et al. Azithromycin synergizes with cationic antimicrobial peptides to exert bactericidal and therapeutic activity against highly multidrug-resistant Gram-negative bacterial pathogens. *EBioMedicine*. 2015;2(7):690-698.  
[PUBMED](#) | [CROSSREF](#)
25. Cole LK. Anatomy and physiology of the canine ear. *Vet Dermatol*. 2009;20(5-6):412-421.  
[PUBMED](#) | [CROSSREF](#)
26. Liu GY, Essex A, Buchanan JT, Datta V, Hoffman HM, Bastian JF, et al. *Staphylococcus aureus* golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. *J Exp Med*. 2005;202(2):209-215.  
[PUBMED](#) | [CROSSREF](#)
27. May ER, Kinyon JM, Noxon JO. Nasal carriage of *Staphylococcus schleiferi* from healthy dogs and dogs with otitis, pyoderma or both. *Vet Microbiol*. 2012;160(3-4):443-448.  
[PUBMED](#) | [CROSSREF](#)
28. Courjon J, Hubiche T, Phan A, Tristan A, Bès M, Vandenesch F, et al. Skin findings of *Staphylococcus aureus* toxin-mediated infection in relation to toxin encoding genes. *Pediatr Infect Dis J*. 2013;32(7):727-730.  
[PUBMED](#) | [CROSSREF](#)
29. Gómez-Sanz E, Torres C, Lozano C, Sáenz Y, Zarazaga M. Detection and characterization of methicillin-resistant *Staphylococcus pseudintermedius* in healthy dogs in La Rioja, Spain. *Comp Immunol Microbiol Infect Dis*. 2011;34(5):447-453.  
[PUBMED](#) | [CROSSREF](#)
30. Gharsa H, Ben Slama K, Gómez-Sanz E, Lozano C, Klibi N, Jouini A, et al. Antimicrobial resistance, virulence genes, and genetic lineages of *Staphylococcus pseudintermedius* in healthy dogs in tunisia. *Microb Ecol*. 2013;66(2):363-368.  
[PUBMED](#) | [CROSSREF](#)
31. Melter O, Svec P, Tkadlec J, Doskar J, Kinska H, Pantucek R. Characterisation of methicillin-susceptible *Staphylococcus pseudintermedius* isolates from canine infections and determination of virulence factors using multiplex PCR. *Vet Med (Praha)*. 2017;62(2):81-89.  
[CROSSREF](#)
32. Gómez-Sanz E, Torres C, Lozano C, Zarazaga M. High diversity of *Staphylococcus aureus* and *Staphylococcus pseudintermedius* lineages and toxigenic traits in healthy pet-owning household members. Underestimating normal household contact? *Comp Immunol Microbiol Infect Dis*. 2013;36(1):83-94.  
[PUBMED](#) | [CROSSREF](#)
33. Phumthanakorn N, Fungwithaya P, Chanchaithong P, Prapasarakul N. Enterotoxin gene profile of methicillin-resistant *Staphylococcus pseudintermedius* isolates from dogs, humans and the environment. *J Med Microbiol*. 2018;67(6):866-873.  
[PUBMED](#) | [CROSSREF](#)
34. Jarraud S, Peyrat MA, Lim A, Tristan A, Bes M, Mougél C, et al. *egc*, a highly prevalent operon of enterotoxin gene, forms a putative nursery of superantigens in *Staphylococcus aureus*. *J Immunol*. 2001;166(1):669-677.  
[PUBMED](#) | [CROSSREF](#)
35. Naorem RS, Goswami G, Gyorgy S, Fekete C. Comparative analysis of prophages carried by human and animal-associated *Staphylococcus aureus* strains spreading across the European regions. *Sci Rep*. 2021;11(1):18994.  
[PUBMED](#) | [CROSSREF](#)
36. Blaiotta G, Ercolini D, Pennacchia C, Fusco V, Casaburi A, Pepe O, et al. PCR detection of staphylococcal enterotoxin genes in *Staphylococcus* spp. strains isolated from meat and dairy products. Evidence for new variants of *seG* and *sel* in *S. aureus* AB-8802. *J Appl Microbiol*. 2004;97(4):719-730.  
[PUBMED](#) | [CROSSREF](#)
37. Dicks J, Turnbull JD, Russell J, Parkhill J, Alexander S. Genome sequencing of a historic *Staphylococcus aureus* collection reveals new enterotoxin genes and sheds light on the evolution and genomic organization of this key virulence gene family. *J Bacteriol*. 2021;203(10):e00587-20.  
[PUBMED](#) | [CROSSREF](#)
38. Santoro D, Bunick D, Graves TK, Segre M. Evaluation of canine antimicrobial peptides in infected and noninfected chronic atopic skin. *Vet Dermatol*. 2013;24(1):39-47.e10.  
[PUBMED](#) | [CROSSREF](#)

39. Breathnach RM, Quinn PJ, Baker KP, McGeady T, Strobl E, Abbott Y, et al. Association between skin surface pH, temperature and *Staphylococcus pseudintermedius* in dogs with immunomodulatory-responsive lymphocytic-plasmacytic pododermatitis. *Vet Dermatol*. 2011;22(4):312-318.  
[PUBMED](#) | [CROSSREF](#)
40. Krishna S, Miller LS. Innate and adaptive immune responses against *Staphylococcus aureus* skin infections. *Semin Immunopathol*. 2012;34(2):261-280.  
[PUBMED](#) | [CROSSREF](#)
41. Lautz S, Kanbar T, Alber J, Lämmle C, Weiss R, Prenger-Berninghoff E, et al. Dissemination of the gene encoding exfoliative toxin of *Staphylococcus intermedius* among strains isolated from dogs during routine microbiological diagnostics. *J Vet Med B Infect Dis Vet Public Health*. 2006;53(9):434-438.  
[PUBMED](#) | [CROSSREF](#)
42. Becker K, Roth R, Peters G. Rapid and specific detection of toxigenic *Staphylococcus aureus*: use of two multiplex PCR enzyme immunoassays for amplification and hybridization of staphylococcal enterotoxin genes, exfoliative toxin genes, and toxic shock syndrome toxin 1 gene. *J Clin Microbiol*. 1998;36(9):2548-2553.  
[PUBMED](#) | [CROSSREF](#)